1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Merck/Bayer’s Vericiguat Outcomes Data Less Impressive On Fuller Disclosure

 
• By Joseph Haas

Efficacy seen in reducing hospitalization in high-risk heart failure patients, but not in reducing the risk of cardiovascular death. Analysts say this portends a more niche opportunity for vericiguat.

3d rendering Human Heart
Vericiguat showed ability to reduce hospitalizations in high-risk heart failure patients, but not a mortality benefit

A more than four-month wait for detailed data from the Phase III cardiovascular outcomes trial of Merck & Co. Inc./Bayer AG’s vericiguat underwhelmed compared to the original positive top-line data release. The VICTORIA trial, detailed on 30 March during a virtual presentation at the American College of Cardiology meeting, showed that vericiguat in combination with available heart failure drugs improved the rate of heart failure-related hospitalizations but did not offer an improvement in cardiovascular deaths.

Analysts said these data still leave vericiguat – an oral soluble guanylate cyclase (sGC) stimulator – likely to obtain approval in patients with worsening heart failure, but probably as a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

GSK’s Nucala Set For Dupixent Face-Off After FDA COPD Nod

 
• By Kevin Grogan

The UK major's asthma drug gets a key expanded approval.

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

 
• By Alexandra Shimmings

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

More from R&D

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.